Cinven to acquire a 10% stake in SYNLAB from Elliott.

Cinven, a private equity company, agreed to acquire a 10% stake in SYNLAB, a provider of laboratory diagnostic services, from Elliott, an investment firm. Financial terms were not disclosed. “We see this development as a positive step for SYNLAB. Elliott’s decision to remain an indirect shareholder demonstrates their continued belief in our Group’s potential and future growth. We look forward to working closely with all our shareholders to drive SYNLAB’s success," Mathieu Floreani, SYNLAB CEO.